Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
25 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Apitope International NV - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Apitope International NV - Product Pipeline Review - 2014', provides an overview of the Apitope International NV's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Apitope International NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Apitope International NV including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Apitope International NV's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Apitope International NV's pipeline products Reasons to buy - Evaluate Apitope International NV's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Apitope International NV in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Apitope International NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Apitope International NV and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Apitope International NV - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Apitope International NV and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Apitope International NV Snapshot 5 Apitope International NV Overview 5 Key Information 5 Key Facts 5 Apitope International NV - Research and Development Overview 6 Key Therapeutic Areas 6 Apitope International NV - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Apitope International NV - Pipeline Products Glance 10 Apitope International NV - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Apitope International NV - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Apitope International NV - Drug Profiles 12 ATXMS-1467 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 ATX-MS2 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 ATX-MS3 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 ATX-UV1 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 ATX-UV2 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 ATXF-8117 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ATXGD-459 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Apitope International NV - Pipeline Analysis 19 Apitope International NV - Pipeline Products by Target 19 Apitope International NV - Pipeline Products by Route of Administration 20 Apitope International NV - Pipeline Products by Molecule Type 21 Apitope International NV - Recent Pipeline Updates 22 Apitope International NV - Locations And Subsidiaries 23 Head Office 23 Other Locations & Subsidiaries 23 Appendix 24 Methodology 24 Coverage 24 Secondary Research 24 Primary Research 24 Expert Panel Validation 24 Contact Us 25 Disclaimer 25
List of Tables Apitope International NV, Key Information 5 Apitope International NV, Key Facts 5 Apitope International NV - Pipeline by Indication, 2014 7 Apitope International NV - Pipeline by Stage of Development, 2014 8 Apitope International NV - Monotherapy Products in Pipeline, 2014 9 Apitope International NV - Phase II, 2014 10 Apitope International NV - Preclinical, 2014 11 Apitope International NV - Pipeline by Target, 2014 19 Apitope International NV - Pipeline by Route of Administration, 2014 20 Apitope International NV - Pipeline by Molecule Type, 2014 21 Apitope International NV - Recent Pipeline Updates, 2014 22 Apitope International NV, Subsidiaries 23
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.